
    
      Study design Prospective randomized controlled trial

      Study period Protocol registration approval date - may/31/2016

      Study drug Sonifilan(Sizofiran)

      Study population

        1. Cervical cancer FIGO stage IA2-IVA patients will be participated.

        2. Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma

        3. age 20-75 year

      Treatment Fron the day of radiation therapy started, Sonifilan 20mg, 1amp IM/week for 8weeks

      Concurrent therapy Chemo & radiation therapy

        1. Cisplatin 40mg/m2, day 1, 8, 15, 2, 29, 36

        2. External whole pelvic irradiation 3000-3500 cGy / 6 fractions in high dose rate

      Assessment

        1. Pre-study assessment (within 4weeks before participation) a medical history b informed
           consent c ID number assignment d life quality assessment - fill out EORTC QOQ-C30, CX24,
           SF-36, FSFI e basic information collect

        2. On-study assessment (during study) a complication check b life quality assessment - fill
           out EORTC QOQ-C30, CX24, SF-36, FSFI

      3. Post-study assessment (1week after study finished) a MRI b PAP smear c HPV test d life
      quality assessment - fill out EORTC QOQ-C30, CX24, SF-36, FSFI

      4 Follow-up assessment (every 3 month for 1 year) a Pelvic exam b PAP smear c HPV test d MRI
      (if needed) e PET (if needed) f life quality assessment - fill out EORTC QOQ-C30, CX24,
      SF-36, FSFI 93, 6, 12, 24 month after study finished)
    
  